Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines

Clinical trial NCT05193734 · UNKNOWN

Trial details

NCT number: NCT05193734
Sponsor: University Hospital, Geneva
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Pertussis Vaccine-Preventable Diseases

Start date: 2022-02-07
Primary completion: 2022-08-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.